Drug Trial Radar · NCT05630573
A Study of TNM001 in Chinese Healthy Preterm and Term Infants
Last checked: Nov 19, 2026Latest source record: Jun 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
Oct 25, 2022
Primary completion
Jun 30, 2023
Study completion Jun 30, 2023
Sponsor
- Lead sponsor
- Zhuhai Trinomab Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 1 year
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to evaluate the safety, tolerability and pharmacokinetics (PK) profile of TNM001 injection in healthy preterm and term infants. The main questions it aims to answer are: * the safety and tolerability of TNM001 injection * the pharmacokinetic (PK) profile of TNM001
Conditions
- Respiratory Syncytial Virus Infections
Interventions
TNM001Biological
intramuscular injection
PlaceboBiological
intramuscular injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of TNM001 InjectionTime frame: 150 days post dose
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Hunan Provincial People's Hospital
Changsha, Hunan, China
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China
Linfen People's Hospital
Linfen, Shanxi, China
Yuncheng Central Hospital
Yuncheng, Shanxi, China
West China Second University Hospital, Sichuan University
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.